Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06386146
PHASE1/PHASE2

JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation

Sponsor: Jacobio Pharmaceuticals Co., Ltd.

View on ClinicalTrials.gov

Summary

This study is to evaluate the efficacy and safety of JAB-30355 in adult participants with advanced solid tumors harboring TP53 Y220C mutation.

Official title: A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-30355 in Adult Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

144

Start Date

2024-07-24

Completion Date

2027-07

Last Updated

2026-01-22

Healthy Volunteers

No

Conditions

Interventions

DRUG

JAB-30355

Oral administration

DRUG

JAB-30355

Oral administration

Locations (13)

Research Site

Denver, Colorado, United States

Research site

Lake Mary, Florida, United States

Research site

St Louis, Missouri, United States

Research site

Canton, Ohio, United States

Research site

Cleveland, Ohio, United States

Research Site

Nashville, Tennessee, United States

Research site

Houston, Texas, United States

Research Site

Beijing, Beijing Municipality, China

Research Site

Beijing, Beijing Municipality, China

Research Site

Beijing, Beijing Municipality, China

Research Site

Guangzhou, Guangdong, China

Research Site

Jinan, Shandong, China

Research Site

Shanghai, Shanghai Municipality, China